Get the Stockscreener App
44.39
0.57%
0.25
Boston Scientific Corp stock is traded at $44.39, with a volume of 12.36M.
It is up +0.57% in the last 24 hours and up +1.09% over the past month.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
See More
Previous Close:
$44.14
Open:
$44.45
24h Volume:
12.36M
Relative Volume:
0.83
Market Cap:
$64.33B
Revenue:
$20.62B
Net Income/Loss:
$3.56B
P/E Ratio:
18.61
EPS:
2.3847
Net Cash Flow:
$3.48B
1W Performance:
+3.88%
1M Performance:
+1.09%
6M Performance:
-30.01%
1Y Performance:
-54.60%
1-Day Range:
$43.89
$44.83
1-Week Range:
$42.28
$44.83
52-Week Range:
$41.38
$105.65
Boston Scientific Corp Stock (BSX) Company Profile
Name
Boston Scientific Corp
Sector
Industry
Phone
508-683-4000
Address
300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA
Compare BSX vs ABT, MDT, SYK, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BSX
Boston Scientific Corp
|
44.39 | 64.33B | 20.62B | 3.56B | 3.48B | 2.3847 |
ABT
Abbott Laboratories
|
104.89 | 181.50B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
94.75 | 121.20B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
294.66 | 113.02B | 25.27B | 3.34B | 4.57B | 8.6334 |
EW
Edwards Lifesciences Corp
|
86.60 | 49.92B | 6.30B | 1.07B | 1.09B | 1.8406 |
Boston Scientific Corp Stock (BSX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-07-26 | Initiated | Barclays | Equal Weight |
| Sep-17-26 | Downgrade | Citigroup | Buy → Neutral |
| Jul-31-26 | Downgrade | Argus | Buy → Hold |
| May-29-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-28-26 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-30-26 | Downgrade | Raymond James | Strong Buy → Outperform |
| Oct-03-25 | Downgrade | Erste Group | Buy → Hold |
| Sep-08-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-16-25 | Initiated | Leerink Partners | Outperform |
| Apr-16-25 | Upgrade | Needham | Hold → Buy |
| Jan-10-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Oct-18-24 | Downgrade | Needham | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Feb-01-24 | Upgrade | Mizuho | Neutral → Buy |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| Jun-30-23 | Initiated | CL King | Buy |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| Mar-29-23 | Initiated | UBS | Buy |
| Dec-22-22 | Initiated | Mizuho | Neutral |
| Dec-20-22 | Resumed | Citigroup | Buy |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-06-22 | Initiated | Wolfe Research | Outperform |
| May-27-22 | Upgrade | Needham | Hold → Buy |
| Apr-13-22 | Resumed | Truist | Buy |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| May-26-21 | Downgrade | Needham | Buy → Hold |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Sep-17-20 | Initiated | Truist | Buy |
| Sep-11-20 | Initiated | Wolfe Research | Peer Perform |
| Apr-22-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-01-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Buy |
| Dec-30-19 | Reiterated | Cowen | Outperform |
| Dec-19-19 | Downgrade | Needham | Strong Buy → Buy |
| Sep-05-19 | Resumed | JP Morgan | Overweight |
| Sep-03-19 | Resumed | Barclays | Overweight |
| May-13-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-28-18 | Initiated | UBS | Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Oct-02-18 | Reiterated | Morgan Stanley | Overweight |
| Sep-07-18 | Reiterated | Needham | Strong Buy |
| Sep-04-18 | Upgrade | Jefferies | Hold → Buy |
| Jul-06-18 | Reiterated | Needham | Strong Buy |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Apr-26-18 | Reiterated | Needham | Strong Buy |
View All
Boston Scientific Corp Stock (BSX) Latest News
Boston Scientific (BSX) Rises Higher Than Market: Key Facts - Zacks Investment Research
Why Did J&J Stock Fall After Q3 Earnings Despite Raised Guidance? - Zacks Investment Research
Why Boston Scientific (BSX) Outpaced the Stock Market Today - Zacks Investment Research
China Adult Feeding Tubes and Formula Market Outlook to 2033Revenue, Volume, Pricing, and Company Share | Forecast Data Reveals Market Entry and Expansion Opportunities - GlobeNewswire Inc.
Boston Scientific (BSX) Advances While Market Declines: Some Information for Investors - Zacks Investment Research
Boston Scientific Corporation (BSX) is Attracting Investor Attention: Here is What You Should Know - Zacks Investment Research
Boston Scientific (BSX) Names Joseph Fitzgerald COO, Restructures Segments Starting 2027 - GuruFocus
Form 8-K BOSTON SCIENTIFIC CORP For: Oct 01 - StreetInsider
Boston Scientific names Fitzgerald COO, creates three segments By Investing.com - Investing.com Canada
Three business units will be created at Boston Scientific in January. - Stock Titan
Stryker (SYK) vs Boston Scientific (BSX): Which is a Better Stock to Buy? - Yahoo Finance
Global Bioelectronic Medicine Market Anticipates Impressive Growth Trajectory of ~10% by 2034 | DelveInsight - GlobeNewswire Inc.
Can J&J's MedTech Business Rebound in Q3 After Q2 Slowdown? - Zacks Investment Research
Bernstein cuts Boston Scientific stock price target on device competition - Investing.com
Bernstein Keeps Their Buy Rating on Boston Scientific (BSX) - The Globe and Mail
Boston Scientific (BSX) Receives a Buy from RBC Capital - The Globe and Mail
Bernstein Keeps Their Buy Rating on Boston Scientific (BSX) - The Globe and Mail
Boston Scientific Corporation (BSX) Stock Forecasts - Yahoo Finance
Boston Scientific (BSX) Stock Sinks As Market Gains: What You Should Know - Zacks Investment Research
Boston Scientific Corp. stock underperforms Friday when compared to competitors - MarketWatch
Boston Scientific Corp. stock underperforms Friday when compared to competitors - MarketWatch
If You Invested $1000 In Boston Scientific Stock 15 Years Ago, You Would Have This Much Today - Benzinga
Boston Scientific stock hits 52-week low at 42.14 USD - Investing.com
Can ISRG Offset China Weakness With Expansion in India and Japan? - Zacks Investment Research
Boston Scientific Corporation (BSX) Stock forecasts - Yahoo Finance Australia
Elutia receives $8 million escrow from Boston Scientific sale - Investing.com
Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029 - marketscreener.com
Boston Scientific's MedSurg Diversification Bolsters Growth Prospects - Zacks Investment Research
Boston Scientific stock absorbs a USD 20.00 target cut - AD HOC NEWS
Boston Scientific stock ahead of the Xetra open as newsroom lists cybersecurity update - AD HOC NEWS
Is Boston Scientific (NYSE:BSX) Facing a Real Market Test? - Kalkine Media
Boston Scientific (BSX) Secures $135.7M Cardiovascular Contract with U.S. Military - GuruFocus
Could Boston Scientific’s $300 Million Cyber Hit Be Mostly a 2026 Problem? - Yahoo Finance
Why Oppenheimer Cut Boston Scientific’s Price Target by $20 Despite Keeping its Outperform Rating - Yahoo Finance
FDA Flags Boston Scientific Catheter Recall - Benzinga
FDA Flags Boston Scientific Catheter Recall - Benzinga
Boston Scientific (BSX) Faces A Recall, Is The 28% Undervaluation Still Compelling? - Yahoo Finance
FDA Finally Approves Watchman Device from Boston Scientific - Medical Product Outsourcing
BSX.GE Bond Profile: Coupon and Redemption - TradingView
Boston Scientific Corp. stock underperforms Friday when compared to competitors - MarketWatch
Mexico Cardiac Rhythm Management Devices Market Outlook to 2036 Provides Revenue, Volume, Pricing and Competitive Insig - GlobeNewswire Inc.
Boston Scientific (BSX) Stock Moves 2.74%: What You Should Know - Yahoo Finance
Will Boston Scientific's Upcoming Launches Fuel the Next Growth Phase? - Zacks Investment Research
Citi downgrades Boston Scientific on uncertain recovery path - Yahoo Finance
Boston Scientific: A Great Company At A Deeply Discounted Price (Rating Upgrade) - Seeking Alpha
Why Did BSX Cut FY26 Guidance? CEO Details Three Unanticipated Factors At Bernstein Conference - Stocktwits
Boston Scientific stock falls as cyberattack clouds 2026 outlook - ad-hoc-news.de
Is Boston Scientific (BSX) a Buy as Wall Street Analysts Look Optimistic? - Yahoo Finance
Boston Scientific fully restores operations after cyberattack - Yahoo Finance
What Is Moving the Story Around Boston Scientific (BSX)? - Kalkine Media
Boston Scientific Corp Stock (BSX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Boston Scientific Corp Stock (BSX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Morano Susan E | Director |
Aug 25 '26 |
Buy |
49.22 |
2,040 |
100,408 |
13,784 |
| Habiger David C | Director |
Aug 05 '26 |
Buy |
47.59 |
2,100 |
99,937 |
17,160 |
| Habiger David C | Director |
Aug 04 '26 |
Buy |
48.59 |
140 |
6,802 |
15,060 |
| Mahoney Michael F | Chairman, President & CEO |
Aug 03 '26 |
Buy |
48.33 |
186,240 |
9,001,408 |
1,590,024 |
| Habiger David C | Director |
Aug 03 '26 |
Buy |
48.07 |
1,042 |
50,084 |
14,920 |
| LUDWIG EDWARD J | Director |
Jul 31 '26 |
Buy |
45.48 |
5,000 |
227,400 |
30,359 |
| Monson Jonathan | EVP and CFO |
Jul 01 '26 |
Option Exercise |
0.00 |
2,087 |
0 |
40,073 |
| Pegus Cheryl | Director |
May 20 '26 |
Buy |
56.49 |
1,770 |
99,987 |
1,770 |
| LUDWIG EDWARD J | Director |
May 20 '26 |
Buy |
56.68 |
3,580 |
202,914 |
25,359 |
| Habiger David C | Director |
May 20 '26 |
Buy |
55.92 |
2,250 |
125,819 |
13,878 |
1.70%
0.98%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):